ISSCA has announced its sponsorship of XXVI Jornadas Mediteraneas – Mediterranean Days of Therapeutic Confrontations in Medicine and Cosmetic Surgery to be held in Barcelona, Spain May 11 – 13, 2018. ISSCA has committed to sponsoring the event for five consecutive years.

MIAMI, Jan. 15, 2018—The International Society for Stem Cell Application (ISSCA) has announced its sponsorship of XXVI Jornadas Mediteraneas -Mediterranean Days of Therapeutic Confrontations in Medicine and Cosmetic Surgery in Barcelona, Spain May 11 – 13, 2018. ISSCA has committed to sponsoring Jornadas Mediteraneas for five consecutive years.

Global Stem Cells Group CEO and medical marketing expert Benito Novas will launch his new book, “Digital Marketing in Your Aesthetic Clinic” in Europe during the event. He will also speak about the latest digital marketing strategies critical to physicians looking to grow their practices.

Additionally, Alfredo Hoyos,M.D., world-renowned plastic surgeon and  Global Stem Cell Group’s chief scientific officer (CSO) will speak about utilizing stem cells to obtain better results in aesthetic surgery procedures.

The event, one of the most influential European medical conferences, will focus on topics such as regenerative medicine and stem cell therapies, skin aging, body rejuvenation and remodeling, and 21st Century tools for professional practices to capture and retain new patients. ISSCA will host two master regenerative medicine certification training classes during the conference. The conference will be held at Hotel Meliá Sitges in Barcelona.  –more—     To learn more about XXVI Jornadas Mediteraneas and register to attend, visit the Stem Cell Conference website, email mailto:info@stemcellsgroup.com, or call 305-560-5337.

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

About ISSCA:
ISSCA 2018 training agenda

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

###

 

 

 

 

 

 

 

 

MIAMI, Jan. 15, 2018 – Global Stem Cells Group,  a world leader in stem cell and regenerative medicine, will host its South American Regenerative Medicine Symposium August 23, 24, and 25th in Buenos Aires, Argentina. This will be GSCG’s fifth consecutive year hosting the symposium.

The main topic for the 2018 event is “Next Generation Medicine: Adult Stem Cells.”

Universidad de Buenos Aires

The symposium will again be hosted at the Faculty of Medicine of the Universidad de Buenos Aires, and will provide an opportunity to showcase advancements in adult stem cell research and therapies on a global level and establish a dialogue among some of the world’s leading stem cell experts. Ten international speakers will share their clinical experience improving the quality of patients’ lives using adult stem cell therapies.

According to Benito Novas, Global Stem Cells Group CEO, the symposium will showcase advances in adult stem cell research and therapies.

“This year’s symposium will highlight the strides stem cell research has made in adult stem cell applications,” Novas says. “

Since 2014, Global Stem Cells Group worked with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the healthcare industry while offering new hope for sufferers of chronic, debilitating conditions.

To learn more about the Fifth Annual South American Regenerative Medicine Symposium visit the Stem Cell Conference website,  email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

 

 

 

 

 

 

Image: Benito Novas

 

Global Stem Cells Group founder and CEO Benito Novas was recognized as a leader in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.

MIAMI, Dec. 22, 2017—Benito Novas, founder and CEO of Global Stem Cells Group (GSCG), earned recognition for his leadership in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.

Novas accepted the recognition, signed and presented to him by Congress President Rector Doctor Arturo Conde at the event, honoring him for helping thousands of physicians around the world bring regenerative medicine therapies to their clinical practices.

Novas provided training and equipment to physicians throughout South America, North America, Europe, Asia, and the Middle East through GSCG affiliate companies Stem Cell Training, Adimarket online regenerative medicine store, and Stem Cell Center Network (present in more than 30 cities globally).

Novas is a global entrepreneur, manager, and keynote speaker with expertise in the field of specialized marketing focused on biotechnology, life sciences, and healthcare development.

The philosophy that has driven him to launch and grow his companies is the desire for a perpetual flow of knowledge and innovation with regard to the role of stem cells in modern medicine.

“My aim is to accelerate the process of getting promising stem cell research and technology developed into treatments and therapies, and to make them readily available to benefit the health and well-being of a broad range of patients,” he says.

Using specialized marketing techniques focused on stem cells and their impact on the field of aesthetic surgery, Novas created a multi-company corporation based on his visionary approach to healthcare management and regenerative medicine.

To learn more about Global Stem Cells Group, visit the company website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

Benito Novas recognized

 

 

 

 

 

 

 

Adimarket, a subsidiary of Global Stem Cells Group, has announced an agreement with biotechnology company Alolotl Biologix to distribute biological products for regenerative medicine applications worldwide.

 MIAMI, Dec.21, 2017— Adimarket, a subsidiary of Global Stem Cells Group (GSCG), and its subsidiary has announced an agreement with Phoenix, Arizona-based Alolotl Biologix to distribute the biotechnology company’s products for regenerative medicine applications worldwide.

Alolotl Biologix focuses on research to optimize the use of human biologicals and to develop biological-related products to foster regeneration and healing for a range of conditions, including orthopedic impairments, wound care, pain management, ophthalmic, cardiovascular, cosmetic, and more.

Adimarket will make the following amniotic liquid products available to qualified practitioners through its online store www.adimarket.net:

AxoBioFluid® C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
  • Contains extracellular matrix components for cellular   attachment and proliferation
  • Cryopreserved for an extended shelf life

AxoBioFluid® physician benefits

  • Procedures are efficient and do not require special instrumentation.
    •  The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
    •  A library of research papers to demonstrate efficacy degenerated tissue is provided.

AxoBioFluid® patient benefits

Relevant Conditions

AxoBioFluidâ C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
  • Contains extracellular matrix components for cellular   attachment and proliferation
  • Cryopreserved for an extended shelf life

AxoBioFluidâ physician benefits

  • Procedures are efficient and do not require special instrumentation.
    •  The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
    •  A  library of research papers to demonstrate efficacy is provided.

AxoBioFluid® Amniotic Allograft Cryopreserved Liquid is a cryopreserved liquid allograft derived from the placental components of the amnion to advance soft tissue repair, replacement, and reconstruction. It is classified as minimally manipulated under FDA regulation 21 CFR Part 1271 and section 361 of the PHS. Benefits of AxoBioFluid® AxoBioFluid® is a human allograft fluid derived from the amniotic layer of the placenta. The two primary cell lines which reside in the amnion are human mesenchymal stromal cells (hMSC) and human amnion epithelial cells (hAEC). Both of these cells are considered to be pluripotent stem cells. AxoBioFluid® contains growth factors released while amniotic cells are grown in culture such as epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and transforming growth factor – beta (TGF-β). These proteins are essential for fetal growth and development and express significant therapeutic benefits when used as a treatment for various injuries and degenerative conditions. AxoBioFluid® is immuneprivileged, anti-inflammatory, anti-fibrotic, pro-vascular, and cytoprotective because of the cells being sourced from the amnion. These secreted factors also signal endogenous progenitor cells to promote regeneration and repair of damaged or degenerated tissue.

AxoBioFluid

  • Degenerative disorders such as osteoarthritis
    • Joint pain
    • Inflammatory conditions such as:
  • Bursitis
  • Tendonitis
  • Fasciitis
  • Epicondylitis
  • Soft tissue injuries such as:
  • Ligament & Tendon sprains
  • Muscle & Meniscus tears
  • Wound Care

AxoBioMembrane, a dehydrated allograft membrane patch derived from the amnion that advances wound repair, skin replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • Contains extracellular matrix components for cellular attachment and proliferation
  • Dehydrated and terminally e-beam sterilized for an extended shelf life.

AxoBioMembraneä Amniotic Allograft Membrane, like all allograft tissue products, has been subjected to recovery microbiological study and has been terminally sterilized with electron beam sterilization.  It works by forming fibrin-elastin bonds at the wound site, ensuring excellent wound adherence. This generates a barrier that protects exposed nerve endings from irritants, providing pain relief while creating a favorable environment for tissue repair and regeneration. In addition, the AxoBioMembrane™ prevents excessive moisture loss by creating a vapor barrier at the wound surface. Growth factors present in the membrane are released into the wound bed, promoting angiogenesis leading to new blood supply needed for cellular migration, proliferation and ultimately, wound repair. Infection is one of the biggest concerns with chronic wounds. AxoBioMembrane™ functions as a bacteriostatic agent, which can inhibit the growth of bacteria at the wound site and reduce the rate infection. It has also been reported to have anti-fibrotic properties, which can reduce scarring. The membrane contains glycoprtoteins found exclusively in the amnion. AxoBioMembrane™ lacks specific surface antigens, which make it immune-privileged and anti-inflammatory.

AxoBioMembraneä physician benefits

  • Procedures are efficient and do not require special instrumentation.
  • AxoBioMembrane™ is billed as patient pays, which makes it a great alternative revenue source.
  • We provide a library of research and white papers to demonstrate efficacy.

AxoBioMembraneä  patient benefits:

  • Pain Reduction
  • Wound Adherence
  • Less Scarring
  • Faster Healing
  • Neovascularization
  • Wound Barrier
  • Anti-bacterial
  • Immune Privileged

AxoBio products are available to purchase on the Adimarket Website.

For more information, visit the Adimarket regenerative medicine online store website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world. 


About Adimarket:

Adimarket, Inc.,
a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

About Alolotl Biologix:
amniotic biofluid
Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue, medical technologies that are disrupting traditional, more invasive, painful, and expensive treatment protocols. For more information, visit www.axobio.com.

###

 

amniotic biofluid

Escazú, Costa Rica

 

 

 

 

Image: CIMA Hospital in Escazú

 

 

Global Stem Cells Group announces plans to expand its Stem Cell Center Network to include a new stem cell treatment center in Escazú, Costa Rica.

MIAMI, Dec. 21, 2017—Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, has announced the opening of a new stem cell center in its Stem Cell Center Network in Escazú, Costa Rica. The new center will focus on treating patients who suffer from regenerative illnesses.

The new center, located at the CIMA Hospital in Escazú, will be headed by Leslie Mesen, M.D., a specialist in anti-aging medicine.

The new center is part of Global Stem Cells Group’s worldwide expansion of its clinical presence, partnering with qualified physicians experienced in stem cell therapies to open new clinics and utilize GSCG stem cell products and protocols inpatient treatments. GSCG has established similar alliances in 33 cities worldwide.

The new center’s location at the CIMA Hospital in Escazú offers a safe and luxurious venue for patients traveling from the U.S. and other countries for treatment.

Mesen studied medicine at the Ibero-American University (UNIBE) in San José, Costa Rica. He leads numerous regenerative medicine courses in the United States and throughout Latin America. He is board certified in anti-aging and regenerative medicine by The American Academy of Anti-Aging Medicine.

Mesen has served as chief medical officer of three highly-recognized anti-aging institutes, including the Costagenics Age Management program (2007-2010), Anti-Aging Institute of the Americas (2010-2013) and the Anti-Aging and Wellness Clinic (2014-present).

The new center in Escazú is equipped with the latest, cutting-edge regenerative medicine technology. Mesen was trained in Global Stem Cells Group facilities in the U.S.

“This new center, headed by Dr. Mesen, is a perfect reflection of Global Stem Cells Group’s commitment to meet the growing needs of clients and patients,” says GSCG founder and CEO Benito Novas. “Together with Dr. Mesen, we will continue to provide the latest medical technology and benefits available through our regenerative medicine products and protocols.

Global Stem Cells Group hopes to approve five more franchises in early 2108. If you are a pysician interested in learning more about joining the world’s largest regenerative medicine practitioner network please contact us www.stemcellcenter.net

GSCG provides stem cell treatments for a variety of conditions, diseases, and aesthetic treatments at facilities worldwide. The new facility will have an international staff experienced in administering the leading cellular therapies available.

Global Stem Cells Group’s Escazú clinic is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. GSCG clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

GSCG is committed to providing the highest standards of services and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

To learn more about Global Stem Cells Group, visit the GSCG website,  email info@stemcellsgroup.com, or call +1305 560 533

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell Group’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

 

 

Escazú, Costa Rica.

Maritza Novas recognized

Global Stem Cells Group Research Director Martiza Novas Recognized for Her Work in Regenerative Medicine

MIAMI, Dec. 22, 2017—Maritza Novas Research Director, Global Stem Cells Group, earned recognition for her work and achievements in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.

Novas has been in the forefront of medical and anti-aging medicine since 2001. The recognition, signed and presented to her by Congress President Rector Doctor Arturo Conde at the event, honored her for 10 years of dedicated service educating others on clinical applications of stem cells.

A pioneer in the use of stem cells for therapeutic procedures, pain management, and treatment of chronic degenerative conditions, Novas has trained more than 2,000 physicians worldwide on procedures and protocols for harvesting and isolating adipose-derived stem cells for autologous re-implantation, and with problem-solving methods to improve patient outcomes.

Novas specializes in stem cell procedures for anti-aging applications, tissue regeneration, functional medicine, age management, bio-identical hormone therapy, and weight control. Novas has been a certified ISSCA specialist for more than four years.

As a member of Stem Cell Training, Inc.’s research and development team, Novas has assisted in the development of new proprietary adipose and bone marrow protocols currently being used in the company’s comprehensive stem cell training courses.

Novas earned a medical degree at the University of Havana, Cuba in 1993. Novas, Director of Research and Development for Global Stem Cells Group, has been in the forefront of medical and anti-aging medicine since 2001.

She has been a member of the American Academy of Anti-Aging Medicine since 2004 and draws upon 10 years of combined experience with therapeutic procedures, hormonal replacement and nutritional therapies, liposculpture, and fat transfers. Novas is currently completing a master’s degree in Molecular Biology at Lehigh University.

For more information, visit the Global Stem Cells Group website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

 

Maritza Novas recognized

StemData relaunch

Global Stem Cells Group has announced the relaunch of its StemData cloud-based electronic medical record system specifically designed for regenerative medicine practitioners.

MIAMI, Nov. 29, 2017—Global Stem Cells Group, a world leader in stem cell and regenerative medicine, has announced the relaunch of its StemData software, the first cloud-based electronic medical record system specifically designed for regenerative medicine practitioners.

The StemData system, initially launched in September 2016, is a customized software program for physicians who operate a regenerative medicine practice. The StemData software empowers physicians to follow patients throughout their treatment schedules. The StemData program comes programmed with the latest point-of-care regenerative medicine protocols and follow-up procedures to make it easy for stem cell patients to schedule appointments by phone, and for practitioners to document patient progress and gather important data to establish the safety and efficacy of stem cell treatments in the physician’s office environment.

The StemData system app is marketed exclusively through Global Stem Cells Group and will be provided free of charge to affiliate physicians in the Stem Cell Center network.

StemData’s cloud-based, server-less solution is accessible via web, iPad, iPhone, Google Glass and Apple Watch. Global Stem Cells Group has utilized the development of the latest electronic medical record (EMR) systems to bring intelligent EMR technology to regenerative medicine specialists.

The StemData app helps regenerative medicine practitioners increase efficiencies in their medical practices while improving both treatment and business outcomes. The app will intuitively adapt to each individual practitioner’s unique practice preferences.

To learn more about GSCG’s StemData solution, visit http://www.stemdata.org, email info@stemcellsgroup.com, or call +1305 560 5337.

About Global Stem Cells Group:

stemdata relaunch


Global Stem Cells Group
(GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell Group’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

stemdata relaunch

ISSCA Buenos Aires

The International Association for Stem Cell Application moved to a new office at Piedra 383 at Ciudad Autonoma of Buenos Aires, Argentina. The move accommodates ISSCA’s increasing specialty and patient volume, as well as its expanding regenerative medicine certification training programs.

MIAMI, Nov. 29, 2017—The International Association for Stem Cell Application (ISSCA) has announced the move of its Puerto Madero office in Buenos Aires to a new location just a few blocks away to Piedra 363. The new location will house an ISSCA regional office and treatment center.

ISSCA Buenos Aires

The move to the larger office reflects ISSCA’s need to accommodate rapidly expanding patient volume and specialty offerings at its Buenos Aires center. The larger clinical and office space will allow ISSCA to continue providing superior services to patients traveling from the U.S, and worldwide for regenerative medicine treatments. The new location includes a dedicated conference room to host ongoing regenerative medicine training programs and more than three new procedure rooms.

ISSCA celebrated the new location’s grand opening Nov. 26-27, 2017, and host ISSCA regenerative medicine certification training courses for physicians.

To learn more about the ISSCA’s Buenos Aires center and training courses, visit the ISSCA website, email info@stemcellsgroup.com, or call 305-560-5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

###

ISSCA Buenos Aires

Magellan Autologous

                                                                            Magellan Autologous Platelet Separator

Global Stem Cells Group and its subsidiary Adimarket named representatives for Magellan Autologous Platelet Separator in Latin America and Middle East.

 MIAMI, Nov. 29, 2017— Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, and its subsidiary Adimarket have been named to represent the Magellan Autologous Platelet Separator in Latin America and Middle East.

Developed by Arteriorcyte Medical Systems, a leading medical device company headquartered in Hopkinton, Mass., the Magellan Autologous Platelet Separator is a high-tech, automated dual spin processing system designed for use in clinical laboratories or intraoperatively at the point-of-care for safe and rapid preparation of high-quality, platelet-rich plasma (PRP) as well as platelet poor plasma (PPP).

Global Stem Cells Group CEO Benito Novas says the Magellan system is a perfect fit for GSCG and Adimarket’s ever-growing list of high-tech regenerative medicine products and equipment, made available to physicians and qualified practitioners through the Adimarket online store.

“We share Arteriocyte’s commitment to research and development of blood component technology to advance treatments that benefit patients in the field of regenerative medicine,” Novas says. “The Magellan system furthers GSCG’s drive to invest in platelet separation technologies that focus on the development of new surgical applications for PRP and elevates these technologies to the next level.”

The fully-automated Magellan system is specifically designed to fractionate blood at bedside without a need for manual manipulation. At the end of its cycle, the Magellan PRP is delivered into a collection syringe, ready for immediate application.

As an industry leader, Adimarket added the Magellan Autologous Platelet Separator System to its online regenerative medicine store to allow physicians to meet the specific needs of each patient with fully customizable product volumes and platelet concentrations. The system can be programmed to deliver a volume of 3 – 10 mL from each processing cycle, allowing practitioners to customize the concentration per mL within the PRP.  The Magellan system is approved for three processing cycles per disposable separation chamber, allowing for a maximum of 30 mL of product.

For more information, visit the Adimarket regenerative medicine online store website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

About Arteriorcyte Medical Systems:
Magellan Autologous Platelet Separator
Arteriocyte Medical Systems, Inc. is a leading medical device company committed to developing and marketing novel medical products to help patients heal faster. Established in 2007 by Arteriocyte, Inc. and DW Healthcare Partners, Arteriocyte Medical Systems is devoted to providing innovative solutions to patients and medical professionals to address serious unmet medical needs particularly in cardiac, orthopedic and vascular surgeries.

###

Magellan Autologous platelet separator

ISSCA Miami

ISSCA will conduct the first regenerative medicine certification training course for the upcoming year in Miami Feb. 2-3, 2018. The two-day course focuses on pain management and aesthetic regenerative medicine protocols.

MIAMI, Nov. 20, 2017—The International Society for Stem Cell Application (ISSCA) announced plans to hold its first regenerative medicine certification training course of the upcoming year Feb. 2 – 3, 2018 in Miami.

The two-day, hands-on training course focuses on pain management and aesthetic regenerative medicine protocols. Practitioners learn skills that can be used to treat patients in their practices, and for career advancement. The course provides participating physicians with training in stem cell applications to benefit patients undergoing aesthetic procedures or being treated for specific medical condtions.

Participating physicians will also receive access to the online stem cell training course to review all content and procedures introduced in the 2-day clinical training course, patient forms and guidelines, procedure informed consent forms, didactic lectures, training booklets, and more.

The ISSCA pain management and aesthetic regenerative medicine protocols training course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose tissue and bone marrow.

Stem cell therapies continue to revolutionize the anti-aging aesthetics industry and help improve the quality of life for patients suffering from some chronic conditions.

To learn more about the training course and register to participate, visit the Stem Cell Training Course website, email info@stemcellsgroup.com, or call 305-560-5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.